Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease

Trial Profile

A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vafidemstat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms ETHERAL-US
  • Sponsors Oryzon
  • Most Recent Events

    • 29 May 2019 According to an Oryzon media release, the first patient in the US has been enrolled.
    • 29 May 2019 According to an Oryzon media release, this trial received IND approval by the FDA on March 15th.
    • 20 May 2019 According to an Oryzon media release, the company announced that the Board of Directors of the Alzheimers Drug Discovery Foundation has approved a grant of 1.5 million dollar to Oryzon Genomics S.A. to support the US-arm of this study. This arm will involve multiple sites in the US and plans to enroll up to 30 patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top